As a result, this study retrospectively examined variations in ER, PR, and HER2 expression in 589 breast cancer patients treated with NAT to assess the effect of NAT on the status of these biomarkers and to investigate the clinicopathological causes of these variations. This evidence concerns the gene PGR and breast carcinoma.